Ifosfamide-based chemotherapy regimens in treatment of lymphoma: the M.D. Anderson experience.
Investigators at M.D. Anderson Cancer Center in Houston first began investigations with the drug ifosfamide in the early 1970s. This alkylating agent has proven to be a valuable drug with easily manageable side effects in therapy of lymphomas. They have described prognostic factors for relapsed lymphomas using this drug in various combinations and have found it of major value in both cytoreduction and stem cell mobilization prior to transplant. The drug has subsequently become part of many established regimens for treatment of lymphoma, and newer combinations containing this drug should be further studied.
Hagemeister
F B
FB
Department of Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA. fhagemei@aol.com
Donato
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000592:standards; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage*; D008223:Lymphoma / Q000188:drug therapy* / Q000628:therapy
D007069:Ifosfamide